ArticleJournal of neurology, neurosurgery, and psychiatry2017
Stability of mild cognitive impairment in newly diagnosed Parkinson's disease.
Article in Journal of neurology, neurosurgery, and psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Best practice guidelines for the diagnosis, evaluation, and management of cognitive disorders in Parkinson's disease.Age and ageing · 2026Guideline
- The identification of cognitive impairment in Parkinson's disease using biofluids, neuroimaging, and artificial intelligence.Frontiers in neuroscience · 2024Pooled it
- Progression of Cognitive Decline in Parkinson's Disease.Journal of Parkinson's disease · 2018Pooled it
- Home-Based, Virtually Supervised Combined Exercise Intervention in People With Parkinson Disease: Protocol for a Randomized Controlled Trial.JMIR research protocols · 2026Article
- Predicting Cognition and Affective Changes in Newly Diagnosed Parkinson's Disease Through Longitudinal Data-Driven Clustering.Journal of geriatric psychiatry and neurology · 2026Article
- Serum phosphorylated tau 217 inJournal of Parkinson's disease · 2026Article
- Factors associated with self- perceived speech impairment inFrontiers in aging neuroscience · 2026Article
- Cumulative incidence and risk factors of dementia in Parkinson's disease and parkinsonism: a population-based study.Brain communications · 2026Article
- Implications and opportunities regarding biological frameworks in overt and prodromal dementia with Lewy bodies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Inflammatory changes in early dementia with Lewy bodies.Frontiers in neurology · 2025Article
- Research progress of multimodal biomarkers in the early diagnosis of mild cognitive impairment in Parkinson's disease.Frontiers in neurology · 2025Review
- Machine Learning for Early Detection of Cognitive Decline in Parkinson's Disease Using Multimodal Biomarker and Clinical Data.Biomedicines · 2024Article
- Cognition and Activity of Daily Living Function in people with Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- GWAS Identifies DPP6 as Risk Gene of Cognitive Decline in Parkinson's Disease.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Article
- A review of the neurotransmitter system associated with cognitive function of the cerebellum in Parkinson's disease.Neural regeneration research · 2024Review
- Prodromal dementia with Lewy bodies in REM sleep behavior disorder: A multicenter study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Predicting the occurrence of mild cognitive impairment in Parkinson's disease using structural MRI data.Frontiers in neuroscience · 2024Article
- Beta amyloid deposition and cognitive decline in Parkinson's disease: a study of the PPMI cohort.Molecular brain · 2022Article
- Time-course of decline in different cognitive domains in Parkinson's disease: a retrospective study.Journal of neural transmission (Vienna, Austria : 1996) · 2022Article
- Neuropsychological changes in FMR1 premutation carriers and onset of fragile X-associated tremor/ataxia syndrome.Journal of neurodevelopmental disorders · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMild cognitive impairment (MCI) is common in early Parkinson's disease (PD). We evaluated the stability of PD-MCI over time to determine its clinical utility as a marker of disease.
methods212 newly diagnosed participants with PD were recruited into a longitudinal study and reassessed after 18 and 36 months. Participants completed a range of clinical and neuropsychological assessments. PD-MCI was classified using Movement Disorders Society Task Force level I (Montreal Cognitive Assessment <26) and level II (using cut-offs of 1, 1.5 and 2SD) criteria.
resultsAfter 36 months, 75% of participants returned; 8% of patients had developed a dementia all of which were previously PD-MCI. Applying level I criteria, 70% were cognitively stable, 19% cognitively declined and 11% improved over 36 months. Applying level II criteria (1, 1.5 and 2SD), 25% were cognitively stable, 41% cognitively declined, 15% improved and 19% fluctuated over 36 months. 18% of participants reverted to normal cognition from PD-MCI. DISCUSSION: Cognitive impairment in PD is complex, with some individuals' function fluctuating over time and some reverting to normal cognition. PD-MCI level I criteria may have greater clinical convenience, but more comprehensive level II criteria with 2SD cut-offs may offer greater diagnostic certainty.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.